Kendall Capital Partners

EpiBone, Inc. is a biotechnology company based in Brooklyn, New York, focused on developing advanced solutions for bone and cartilage repair. Founded in 2013, EpiBone utilizes patient-specific scans and their own stem cells to create customized bone grafts, which are cultivated in a bioreactor to facilitate growth. The company aims to improve skeletal repair and enhance bone formation and regeneration through its innovative technologies. EpiBone's lead product, a living 3D bone graft, successfully completed its Phase I/IIa clinical trial in August 2023. Additionally, the company is advancing its cartilage repair pipeline, which includes an allogeneic osteochondral plug that received Investigational New Drug approval in July 2023, and an injectable cartilage filler, partly funded by the Department of Defense. Through these developments, EpiBone seeks to revolutionize orthopedic repair and provide patients with more effective treatment options.

Omnipulse Biosciences offers single injection quantities suitable for clinical trials and commercial distribution to low-income countries

EpiBone, Inc. is a biotechnology company based in Brooklyn, New York, focused on developing advanced solutions for bone and cartilage repair. Founded in 2013, EpiBone utilizes patient-specific scans and their own stem cells to create customized bone grafts, which are cultivated in a bioreactor to facilitate growth. The company aims to improve skeletal repair and enhance bone formation and regeneration through its innovative technologies. EpiBone's lead product, a living 3D bone graft, successfully completed its Phase I/IIa clinical trial in August 2023. Additionally, the company is advancing its cartilage repair pipeline, which includes an allogeneic osteochondral plug that received Investigational New Drug approval in July 2023, and an injectable cartilage filler, partly funded by the Department of Defense. Through these developments, EpiBone seeks to revolutionize orthopedic repair and provide patients with more effective treatment options.

Eyenuk, Inc. is a medtech company focused on developing artificial intelligence-based technology for retinal image analysis and disease detection. Founded in 2010 and based in Woodland Hills, California, Eyenuk's flagship product, the EyeArt AI Eye Screening System, is recognized for its extensive validation in the autonomous detection of diabetic retinopathy. The company also offers solutions such as EyeMark, which tracks retinopathy progression, and EyeApp, a mobile application that allows healthcare providers to conduct diabetic retinopathy screenings using smartphones. Additionally, Eyenuk provides EyeSeeAMD, a technology for identifying age-related macular degeneration. The company's mission is to screen every eye globally to ensure timely diagnosis of potentially life-threatening eye diseases, including diabetic retinopathy, glaucoma, and age-related macular degeneration, among others.

Bilayer Therapeutics is a biotechnology company founded in 2020 and based in Cambridge, Massachusetts. The company focuses on developing innovative therapies using bile acids to address various diseases of the colon, including chronic idiopathic constipation, irritable bowel syndrome with constipation, inflammatory bowel disease, ulcerative colitis, Crohn's disease, type 2 diabetes, obesity, and metabolic disorders. By stimulating the body's natural mechanisms for regulating constipation, Bilayer Therapeutics aims to offer first-in-class treatments that enhance patient care for these prevalent gastrointestinal conditions.

Rejuvenate Bio Inc is a biotechnology company based in Brookline, Massachusetts, founded in 2017. The company focuses on developing gene therapies aimed at increasing the health and lifespan of domesticated animals, particularly dogs. Its innovative therapies utilize new DNA instructions to provide anti-aging treatments and address specific diseases in pets. The foundation of Rejuvenate Bio's research is rooted in work from the Wyss Institute at Harvard Medical School, and the company has established a gene therapy pipeline that targets chronic age-related diseases. By leveraging clinically validated gene targets and effective delivery methods, Rejuvenate Bio aims for long-lasting and well-tolerated gene expression, ultimately enhancing the quality of life for both animals and potentially humans facing chronic health challenges.